TNF[alpha] acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-[kappa]B-dependent pathways

Tumor necrosis factor [alpha] (TNF[alpha]) enhances proliferation of chemically-induced mammary tumors and of T47D human cell line through not fully understood pathways. Here, we explored the intracellular signaling pathways triggered by TNF[alpha], the participation of TNF[alpha] receptor (TNFR) 1...

Full description

Saved in:
Bibliographic Details
Published in:Experimental cell research 2008-02, Vol.314 (3), p.509
Main Authors: Rivas, Martín A, Carnevale, Romina P, Proietti, Cecilia J, Rosemblit, Cinthia, Beguelin, Wendy, Salatino, Mariana, Charreau, Eduardo H, Frahm, Isabel, Sapia, Sandra, Brouckaert, Peter, Elizalde, Patricia V, Schillaci, Roxana
Format: Article
Language:English
Subjects:
60 APPLIED LIFE SCIENCES
ANTIBODIES
Binding sites
BORON CHLORIDES
Breast cancer
CARCINOMAS
CELL PROLIFERATION
Cellular biology
GROWTH
IN VITRO
IN VIVO
MAMMARY GLANDS
RECEPTORS
Signal transduction
TUMOR CELLS
TUMOR PROMOTERS
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor [alpha] (TNF[alpha]) enhances proliferation of chemically-induced mammary tumors and of T47D human cell line through not fully understood pathways. Here, we explored the intracellular signaling pathways triggered by TNF[alpha], the participation of TNF[alpha] receptor (TNFR) 1 and TNFR2 and the molecular mechanism leading to breast cancer growth. We demonstrate that TNF[alpha] induced proliferation of C4HD murine mammary tumor cells and of T47D cells through the activation of p42/p44 MAPK, JNK, PI3-K/Akt pathways and nuclear factor-kappaB (NF-[kappa]B) transcriptional activation. A TNF[alpha]-specific mutein selectively binding to TNFR1 induced p42/p44 MAPK, JNK, Akt activation, NF-[kappa]B transcriptional activation and cell proliferation, just like wild-type TNF[alpha], while a mutein selective for TNFR2 induced only p42/p44 MAPK activation. Interestingly, blockage of TNFR1 or TNFR2 with specific antibodies was enough to impair TNF[alpha] signaling and biological effect. Moreover, in vivo TNF[alpha] administration supported C4HD tumor growth. We also demonstrated, for the first time, that injection of a selective inhibitor of NF-[kappa]B activity, Bay 11-7082, resulted in regression of TNF[alpha]-promoted tumor. Bay 11-7082 blocked TNF[alpha] capacity to induce cell proliferation and up-regulation of cyclin D1 and of Bcl-xL in vivo and in vitro. Our results reveal evidence for TNF[alpha] as a breast tumor promoter, and provide novel data for a future therapeutic approach using TNF[alpha] antagonists and NF-[kappa]B pharmacological inhibitors in established breast cancer treatment. [PUBLICATION ABSTRACT]
ISSN:0014-4827
1090-2422
DOI:10.1016/j.yexcr.2007.10.005